checkdown-arrowsearchshare

This site is intended for healthcare professionals outside the U.S.

The OTEZLA® International Website


close x

You are now leaving Otezla.net!


Patients report improved quality of life1

OTEZLA improves physical function, relieves pain, and reduces fatigue1-4

 

SUSTAINED IMPROVEMENT IN PHYSICAL FUNCTION UP TO 3 YEARS1,a

otezla mean improvement in physical function
all manifestations of psoriatic arthritis
a

PALACE 1 study. Data as observed; includes all patients who received OTEZLA 30 mg BID, regardless of whether they were initially randomized to OTEZLA or were placebo patients re-randomized to OTEZLA at week 16 or week 24.

  • Patients taking OTEZLA 30 mg BID achieved significant improvement in quality of life, as measured by reduction in HAQ-DI (disability) score, vs placebo at week 165*

OTEZLA relieved fatigue and reduced pain1,3,6

  • Patients taking OTEZLA 30 mg BID achieved significant improvements in baseline FACIT-F fatigue scores vs placebo at week 16, with an overall improvement of 5.6 points at 2 years
  • Patients taking OTEZLA 30 mg BID achieved significantly greater reductions in baseline pain VAS score vs placebo at week 16, with an overall reduction of -17.4 at 1 year§
*

PALACE 1 study. OTEZLA 30 mg BID vs placebo: -0.24 vs -0.09 (ITT, P = 0.0017).

Pooled analysis of PALACE 1-3. Week 16 improvement in FACIT-F score, OTEZLA 30 mg BID vs placebo: 3.45 (n = 473) vs 1.14 (n = 475); P < 0.001.

Pooled analysis of PALACE 1-3. Week 16 improvement in pain VAS score, OTEZLA 30 mg BID vs placebo: -12.7 (n = 472) vs -5.8 (n = 480), P < 0.0001.

§

Patients randomized to OTEZLA 30 mg BID at baseline who remained on treatment for 52 weeks.

BL, baseline; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; HAQ-DI, health assessment questionnaire-disability index; ITT, intent to treat; PALACE, Psoriatic Arthritis Long-Term Assessment of Clinical Efficacy; VAS, visual analog scale.

References: 1. Kavanaugh A, Gladman DD, Gomez-Reino JJ, et al. Presented at: the Annual European Congress of Rheumatology EULAR 2016; 8–11 June 2016; London, UK. 2016. 2. Mease PJ, Wollenhaupt J, Hall S, et al. Assessment of Disability Levels in a Cohort of 1,489 Patients With Active Psoriatic Arthritis, and the Effect of Apremilast Treatment: Pooled Data From Three Phase III, Randomized, Controlled Trials. Presented at: the 2015 ACR/ARHP Annual Meeting; November 7–11, 2015; San Francisco, CA. 3. Kavanaugh A, Gladman DD, Edwards CJ, et al. Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated With Long-term (104-Week) Improvement in Fatigue in Patients With Psoriatic Arthritis: Pooled Results From 3 Phase 3, Randomized, Controlled Trials. Presented at: the 2015 ACR/ARHP Annual Meeting; November 7–11, 2015; San Francisco, CA. 4. Gladman DD, Strand V, Kavanaugh A, et al. Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Improvement of Pain, Fatigue, and Disability in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials. 2014 ACR/ARHP Annual Meeting. ABSTRACT NUMBER: 1565. 5. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73:1020–1026. 6. Gladman D, Strand V, Kavanaugh A, et al. Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated With Improvement of Pain, Fatigue, and Disability for Up to 52 Weeks in Patients With Psoriatic Arthritis: Results From 3 Phase 3, Randomized, Controlled Trials. Presented at: the 2014 ACR/ARHP Annual Meeting; November 15-19, 2014; Boston, MA.


Select an e-mail client to share

close x